GDRX$1.87
$1.88
Chart
Performance
Key Stats
AI GDRX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralGoodRx Holdings (GDRX) shows potential in its core business but faces headwinds in profitability and technical momentum. Its thematic relevance in healthcare cost savings remains strong, but current valuation and recent performance warrant a cautious approach.
Thematic
GoodRx operates in a continuously relevant theme of healthcare affordability and transparency. The increasing complexity and cost of prescription drugs globally provide a sustained tailwind for its service offering.
Fundamental
GoodRx shows robust revenue and gross profit, but has struggled with net profitability recently. Its balance sheet is solid with manageable debt, and free cash flow is positive, yet P/E ratios indicate a high valuation relative to current earnings.
Technical
The stock has experienced a significant decline over the past year but has shown some recent stabilization. Technical indicators are mixed, with some suggesting oversold conditions while others indicate ongoing downward pressure.
| Factor | Score |
|---|---|
| Healthcare Affordability & Transparency | 90 |
| Digital Health Adoption | 80 |
| Pharmacy Benefit Manager (PBM) Landscape | 70 |
| Competition & Disruption | 65 |
| Subscription & Ancillary Services Growth | 70 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 40 |
| Growth | 55 |
| Balance Sheet Health | 70 |
| Cash Flow | 75 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 50 |
| Volume Confirmation | 65 |
| Support & Resistance | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Improving Profitability
The company has shifted from net losses in previous periods (2021-2023) to a net income of $16.39 million in the latest annual reporting period (2024), indicating a significant turnaround in profitability. Quarterly net income has also shown positive trends, moving from a loss in Q1 2024 to a profit in subsequent quarters.
Lowered P/S Ratio
The trailing Price-to-Sales (P/S) ratio is 3.0, down from 4.4 in 2021, suggesting that the stock may be becoming more reasonably valued relative to its revenue generation capacity.
Bearish Points (7)
High P/E Ratio
The trailing Price-to-Earnings (P/E) ratio is 81.6, and the forward P/E (based on 2024 estimates) is 28.5. Both are high, especially the trailing P/E, suggesting the stock may be overvalued relative to current earnings.
Slowing Revenue Growth
While revenue has grown from $745.42 billion in 2021 to $792.32 billion in 2024, the year-over-year growth rate has been decelerating, with the latest annual revenue growth being modest.
Calendar
August 2025
7
Next Earnings Date
H: $0.12
A: $0.10
L: $0.09
H: 207.50M
A: 205.72M
L: 204.70M
Profile
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solution for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
Seasonals
Price Target
6.32 USD
The 39 analysts offering 1 year price forecasts for GDRX have a max estimate of 9.00 and a min estimate of 4.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major competitor through its Pharmacy Benefit Manager (Caremark) and extensive retail pharmacy network, offering discount programs and telehealth services.
Weight: 90
Dominant player in healthcare through its Optum division, which includes OptumRx, a leading Pharmacy Benefit Manager influencing drug pricing and access.
Weight: 88
Operates Express Scripts, a significant Pharmacy Benefit Manager directly involved in drug benefit management, formularies, and pricing negotiations.
Weight: 85
Significant disruptive force in online pharmacy with Amazon Pharmacy and PillPack; also expanding into broader healthcare services like One Medical, directly competing for prescription fulfillment.